[Hyperplastic scars and keloids: part II: Surgical and non-surgical treatment modalities].
Aberrant wound healing results in unsightly scarring, hypertrophic scarring, and keloid formation, causing functional and cosmetic deformities, discomfort, psychological stress, and patient dissatisfaction. Scar management, both surgical and non-surgical, continue to be important issues for the facial plastic surgeon. Many techniques for the management of hypertrophic scars and keloids have been proven through extensive use, but few are supported by prospective studies with adequate control groups. Several new therapies showed good results in small-scale trials, but these have not been repeated in larger trials with long-term follow-up. This article presents an overview of the available therapies and provides recommendations for the treatment of abnormal scarring. The recommendations focus on the management of hypertrophic scars and keloids. Strategies for the management of keloids and hypertrophic scars are of continuing interest and studies are necessary to understand the basic mechanisms causing aberrant wound healing. In addition, an overview of new developments in molecular wound management and gene therapy, as they relate to facial plastic surgery, is provided.
Baisch
A
A
Universitäts-Hals-Nasen-Ohren-Klinik Mannheim, Klinikum, Theodor-Kutzer-Ufer, 68135, Mannheim.
Riedel
F
F
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D017439:Cicatrix, Hypertrophic / Q000628:therapy*; D003131:Combined Modality Therapy; D017679:Cryotherapy / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007627:Keloid / Q000628:therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D019651:Plastic Surgery Procedures / Q000295:instrumentation / Q000379:methods*; D013524:Surgical Flaps
D000305:Adrenal Cortex Hormones; D000893:Anti-Inflammatory Agents